PET for cancer staging. (Policy & Practice).
Starting Oct. 1, Medicare will cover positron emission tomography scans using [fluorodeoxyglucose.sup.18] (FD G-PET) for staging breast cancer and for restaging locoregional recurrence or metastasis. Fluorodeoxyglucose is a radioactive tracer substance that is drawn to high levels of metabolic activity, as in a tumor. The Centers for Medicare and Medicaid Services announced the coverage decision in a May 2 program memorandum. Medicaid still does not cover PET for initial diagnosis of breast cancer or for initial staging of axillary lymph nodes.
|Printer friendly Cite/link Email Feedback|
|Publication:||OB GYN News|
|Date:||Jun 15, 2002|
|Previous Article:||Contak CD CRT-D System. (New & Approved).|
|Next Article:||Women's health survey. (Policy & Practice).|